Log In
Print this Print this

CAR T cell therapy targeting CD19

  Manage Alerts
Collapse Summary General Information
Company Intrexon Corp.
DescriptionChimeric antigen receptor (CAR)-modified T cells targeting CD19
Molecular Target CD19
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationHematologic malignancies
Indication DetailsTreat CD19-positive lymphoid malignancies
Regulatory Designation
PartnerZiopharm Oncology Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today